BMY Bristol-Myers Squibb Company

CORRECTING and REPLACING Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights

Please replace the release with the following corrected version due to multiple revisions.

The corrected release reads:

BRISTOL-MYERS SQUIBB TO HOLD INVESTOR TELECONFERENCE TO DISCUSS ASCO HIGHLIGHTS

Bristol-Myers Squibb Company (NYSE:BMY) will host a teleconference on Sunday, June 4, 2017, at 7:30 p.m. EDT (6:30 p.m. CDT) to discuss company strategy and review data presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Company executives will provide an overview of company strategy and data presented at the meeting, with a focus on the company’s immuno-oncology portfolio, and address inquiries from investors and analysts.

Investors and the general public are invited to listen to a live webcast of the call at investor.bms.com, by dialing toll free (800) 236-0877 or international (719) 457-1036, confirmation code: 3209540. Materials related to the call will be available at the same website prior to the call. A replay of the call will be available beginning at 11:00 p.m. EDT on June 4 through 11:00 p.m. EDT on June 18. The replay can be accessed at investor.bms.com or by dialing (888) 203-1112 or (719) 457-0820, confirmation code: 3209540.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedInTwitter, YouTube and Facebook.

EN
26/05/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bristol-Myers Squibb Company

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: May 3, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

S&P 500 and Nasdaq 100 Testing Prior 2022 Highs Since late-February (2/25/25 Compass) we expected an 8-10% pullback to provide a buying opportunity. But that all changed in last week's Compass (4/1/25), when we downgraded our outlook to bearish/cautious, citing several concerning developments (SPX and QQQ failure at 200-day MAs, bear flag breakdowns across major indexes targeting 5100-5200 on SPX, high yield spreads widening above 355bps, major tops on market leaders NVDA and META, semiconducto...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Near-Term Downside Likely Following False Breakouts Our long-term outlook remains bullish as long as the S&P 500 remains above 5770-5850 and 5600-5670 (worst case), and we are buyers at these levels. With that said, we see potential for near-term downside as the S&P 500, Nasdaq 100 (QQQ), and FANG+ (FNGS) (1) could not decisively break out to new highs, (2) display bearish false breakouts, (3) have fallen back into their 2+ month trading ranges, (4) are violating their 1+ month uptrends, and (5...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch